Feature | Cath Lab | October 18, 2020

No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

Results from the VOYAGER PAD Trial answer key safety question raised nearly two years ago reported at TCT Connect

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used.[1]

The research was reported today at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF). 

Paclitaxel drug-coated devices, including drug-coated balloons and drug-eluting stents, improve patency of lower extremity revascularization (LER) in patients with peripheral artery disease (PAD). However, meta-analyses published in December 2018 of randomized trials of DCD have reported increased long-term mortality compared with non-DCD.[2] These concerns have led to warnings from regulatory agencies about the use of DCD in patients with PAD. It also spurred a hugh amount of debate in the interventional community about the safety of paclitaxel. At TCT 2019, one day of the FDA town hall meeting was devoted to this topic and the key takeaway was that more data was needed to show either safety of DCDs or to clarify what is causing any increased mortality issues. This is the first large scale study to exmaine this and confirm the safety of paclitaxel devices.

The study also included randomization of patients to the anticoagulant rivaroxaban to confirm or eliminate the potential variable of the drug impacting any increased mortality signal.

“Inverse Probability Treatment Weighting (IPTW) successfully adjusted for known confounders and showed no mortality risk or benefit associated with DCD, including in subgroups by device type,” said Connie N. Hess, M.D., MHS. Hess is an associate professor of medicine (cardiology) at the University of Colorado School of Medicine, Aurora. “This analysis from VOYAGER PAD addresses many of the limitations of currently available data regarding mortality and paclitaxel and adds to the literature examining the safety of drug-coated devices.”

 

VOYAGER PAD Shows No Safety Issues With Paclitaxel

VOYAGER PAD was a double-blind, placebo-controlled trial of PAD patients undergoing LER randomized to rivaroxaban 2.5 mg twice daily or placebo on a background of aspirin 100 mg daily. Clopidogrel was allowed per operator discretion. The primary results of this trial, presented earlier this year at ACC and published in the New England Journal of Medicine,[1] found that rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone.

This analysis examined the long-term safety of DCD and evaluated whether rivaroxaban 2.5 mg twice daily plus low dose aspirin versus low dose aspirin alone on the primary efficacy endpoint was consistent with versus without DCD use.

Deaths were prospectively collected and adjudicated. All-cause mortality, a prespecified secondary outcome, was the primary outcome for this analysis. Device type was collected at enrollment in patients undergoing endovascular LER.

Among 6,564 randomized patients, 66% (n=4,316) underwent endovascular index LER and were included in this analysis; median follow-up was 31 months (IQR 25, 37), and complete ascertainment of vital status was available for 99.6% of patients. During the qualifying endovascular LER, DCD was used for 31% (n=1,358) of patients. Patients receiving DCD more frequently had prior endovascular LER, had higher baseline use of dual antiplatelet therapy and statins, and were more often treated for
claudication than non-DCD patients.

In the unweighted analysis, lower associated mortality was observed among patients receiving DCD versus non-DCD (2.9 vs. 3.9 per 100 patient-years; 3.5-year Kaplan-Meier cumulative incidence of 10.2 vs.13.8%). After weighting, there was no association between DCD use and mortality (3.5-year cumulative incidence 12.1 vs. 12.6%, HR 0.95, 95% CI 0.83-1.09, p=0.49). The benefit of rivaroxaban 2.5 mg twice daily with aspirin compared to aspirin alone on reducing ischemic limb and cardiovascular outcomes was also consistent regardless of whether a DCD was used.

The VOYAGER PAD trial was funded by research grants to CPC Clinical Research from Bayer and Janssen.

Dr. Hess reported the following disclosures: grant/research support to CPC Clinical Research from Bayer, Janssen, Amgen, and Merck; and grant/research support to CPC Clinical Research from the Pan-Industry Consortium including Medtronic, Boston Scientific, Cook, Philips, Bard, Surmodics, and TriReme to support statistical analyses. 

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention — VOYAGER PAD data presented at ACC 2020

VIDEO: Overview of Drug-coated Balloons and the Issue of Paclitaxel Safety — Interview with Juan Granada, M.D.

 

Find additional TCT 2020 news, video and late-breaking studies

 

Reference: 

1. Marc P. Bonaca, Rupert M. Bauersachs, Sonia S. Anand, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. NEJM. Published online March 27, 2020. DOI: 10.1056/NEJMoa2000052.

2.  Konstantinos Katsanos, Stavros Spiliopoulos, Panagiotis Kitrou, et al. Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2018;7. Originally published 6 Dec 2018. https://doi.org/10.1161/JAHA.118.011245.

 

Related Content

Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Videos | TCT

Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...

Home October 04, 2019
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
Feature | TCT

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical ...

Home September 21, 2018
Home
Subscribe Now